Crispr Therapeutics: More Patients, Same Losses
CRISPR Therapeutics AG (CRSP) Presents at AHA Scientific Sessions 2026 - Slideshow
CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy
CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
CRISPR Therapeutics: I Love The Medical Breakthroughs, I Don't Love The Stock - Strong Sell
CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver Transaminases
Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response
CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90
CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70
Why Did CRISPR Therapeutics (CRSP) Stock Slide After Its Latest Update?
CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As It Names A New CTO
CRISPR Therapeutics (CRSP) Appoints Siva Sakhamuri As Chief Technical Officer
Crispr Therapeutics Reports Growing Casgevy Use Ahead of Key Pipeline Data, RBC Says
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $82 Price Target
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.